View More Recent Stories
-
Myriad Genetics (MYGN) PT Raised to $22 at Jefferies
-
Myriad Genetics (MYGN) PT Raised to $30 at TD Cowen
-
Myriad Genetics (MYGN) Completes Sale of EndoPredict Business to Eurobio Scientific, Advances International Reorganization
-
These stocks offer you exposure to rising demand for fertility treatment – Barclays
-
Myriad Genetics (MYGN) Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
-
Scotiabank Starts Myriad Genetics (MYGN) at Sector Outperform, 'meaningful headroom for the stock over the next 12 months'
